Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC-001 and QS-21 in mild to moderate Alzheimer's disease
NCT00498602Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2007
- Primary completion
- Feb 2013
- Modality
- Antibody Conjugates, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of vanutide cridificar in Alzheimer's disease (AD), sponsored by Pfizer. Started Nov 2007; status: completed.
02
Drugs
vanutide cridificar
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00498602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498602.